

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4033730

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT	
NATURE OF CONVEYANCE:	Corrective Assignment to correct the ADDRESS FOR ASSIGNEE CONTAINS TYPO ON NOTICE OF RECORDATION previously recorded on Reel 039011 Frame 0980. Assignor(s) hereby confirms the ADDRESS FOR ASSIGNEE CONTAINS TYPO ON NOTICE OF RECORDATION.	
CONVEYING PARTY DATA		
	Name	Execution Date
	ASTRAZENECA AB	02/18/2016
RECEIVING PARTY DATA		
Name:	SUMITOMO DAINIPPON PHARMA CO., LTD.	
Street Address:	6-8, DOSHO-MACHI 2-CHOME	
Internal Address:	CHUO-KU, OSAKA-SHI	
City:	OSAKA	
State/Country:	JAPAN	
Postal Code:	541-8524	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Patent Number:	8895570
CORRESPONDENCE DATA		
Fax Number:	(202)408-4400	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	ltkach@finnegan.com	
Correspondent Name:	FINNEGAN	
Address Line 1:	901 NEW YORK AVENUE, N.W.	
Address Line 4:	WASHINGTON, D.C. 20001	
ATTORNEY DOCKET NUMBER:	11285.0074-00	
NAME OF SUBMITTER:	LISA TKACH	
SIGNATURE:	/LISA TKACH/	
DATE SIGNED:	09/01/2016	
Total Attachments: 2		
source=Assignment - AZ to Sumitomo#page1.tif		
source=Assignment - AZ to Sumitomo#page2.tif		

ASSIGNMENT

WHEREAS, AstraZeneca AB, whose post office address is SE-151 85 Södertälje, SWEDEN [hereinafter referred to as "ASTRAZENECA"], and Sumitomo Dainippon Pharma Co., LTD., (formerly known as "Dainippon Sumitomo Pharma Co., Ltd.") whose post office address is 6-8, Dosho-machi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8524, JAPAN [hereinafter referred to as "SUMITOMO"], jointly own, by assignments recorded on September 19, 2013 at reel/frame 31242/61 and a reel/frame 31241/967, all right, title and interest in U.S. Patent No. 8,895,570 entitled PURINE DERIVATIVES, and in any inventions claimed therein; and

WHEREAS, SUMITOMO desires to own ASTRAZENECA's entire right, title, and interest in and to U.S. Patent No. 8,895,570 and the inventions claimed therein;

NOW THEREFORE, be it known that, for good and valuable consideration, receipt of which is hereby acknowledged, ASTRAZENECA hereby sells, assigns, transfers and sets over to SUMITOMO, its lawful successors and assigns, ASTRAZENECA'S entire right, title, and interest in and to U.S. Patent No. 8,895,570 and the inventions claimed therein and all reissues, reexaminations and extensions thereof;

AND, ASTRAZENECA HEREBY further covenants that ASTRAZENECA has the full right to convey the interest assigned by this Assignment, ASTRAZENECA will take all action and execute all documents necessary to perfect the interest assigned hereby, and ASTRAZENECA has not executed and will not execute any agreement in conflict with this Assignment;

AND, ASTRAZENECA HEREBY further covenants and agrees that ASTRAZENECA, through its officers and employees, will, without further consideration, communicate with SUMITOMO, its successors and assigns, any facts known to ASTRAZENECA and its officers and employees respecting U.S. Patent No. 8,895,570 and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver all papers that may be necessary or desirable to perfect the title to U.S. Patent No. 8,895,570 in SUMITOMO, its successors and assigns, execute all reissue applications, make all rightful oaths, and generally do everything possible to aid SUMITOMO, its successors and assigns, to enforce U.S. Patent No. 8,895,570 in the United States, it being understood that any expense incident to the execution of such papers shall be borne by SUMITOMO, its successors and assigns.

IN TESTIMONY WHEREOF, each party has caused its authorized representative to execute this Assignment.

ASTRAZENECA AB

By [Signature]

Name: ANDREW COOK

Title: SENIOR PATENT ATTORNEY

Date: 18 FEBRUARY 2016

SUMITOMO DAINIPPON PHARMA CO., LTD.

By [Signature]

Name: Masayo TADA

Title: Representative Director, President and

Chief Executive Officer

Date: 8 April, 2016